Great listen. I liked how Sud referred to IHL as a biotech play...

Great listen.

I liked how Sud referred to IHL as a biotech play and how our clinical assets are going to make the bulk of our value in the future.

His stressing on how the clinical assets would have a lot of value after a Phase 2 human trial, referring to OSA of course foreshadows what is to come.

Currently its pretty obvious that IHL's clinical assets are valued at zero. Quite literally zero.

I made a post a while back that compared IHL to Little Green Pharma with very similar market caps and very similar revenue per quarter.

Clear that the market is only valuing the current oils biz, which itself provides nice upside from here with the growth and dominance of Cannvalate as our partner. But none of our clinical assets are being considered by the market.

Considering that most biotechs ONLY have clinical assets and nothing else yet boast lofty valuations after achieving successful human trial results tells the story of opportunity for IHL. Many multiples from these levels as soon as our clinical assets get validation, its practically like starting from zero when valuing the company's biotech business. Incredible opportunity.